Industry News

prosomnus lawsuit
Dental Sleep Medicine Industry News Sleep Apnea

ProSomnus Prevails in Intellectual Property Lawsuit

ProSomnus Sleep Technologies (“ProSomnus”) has announced a significant victory in its intellectual property enforcement action, reinforcing the Company’s commitment to protecting the innovations, technologies, and proprietary assets that support advances in sleep medicine. The United States District Court for the Southern District of Florida adopted in full the Magistrate Judge’s Report […]

ReDream Brands Launches as the Leading Direct-to-Consumer Platform for Sleep Apnea and Sleep Health
Industry News Professional Practice

ReDream Brands Launches as the Leading Direct-to-Consumer Platform for Sleep Apnea and Sleep Health

Cathay Capital announced the launch of ReDream Brands, a new consumer sleep health platform dedicated to helping millions of people achieve better sleep and healthier lives. The platform brings together four of the industry’s most recognized direct-to-consumer brands: cpap.com, The CPAP Shop, Lofta and sleeping.com, creating a leading platform for […]

CND Life Sciences Secures Growth Financing
Industry News

CND Life Sciences Secures Growth Financing to Expand Syn-One Test

CND Life Sciences announced the completion of growth financing led by S-Curve Partners, an operator-led healthcare investment firm focused on founder-inspired healthcare technology and diagnostics businesses. S-Curve was joined by current CND investors and shareholders, reflecting continued confidence in the Company’s commercial trajectory, expanding clinical adoption, and long-term strategic positioning. […]

FDA Approves Takeda’s ORZEYFUL for Narcolepsy Type 1
Global News Industry News Narcolepsy Pharmacological

U.S. FDA Approves Takeda’s ORZEYFUL, the First and Only Orexin Agonist for Narcolepsy Type 1

Takeda announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. […]